Federica Genovese1, Ahmad Akhgar2, Sung Sam Lim3, Alton B Farris4, Monica Battle5, Jason Cobb6, Dominic Sinibaldi7, Morten A Karsdal1, Wendy I White2. 1. Fibrosis Biology and Biomarkers, Nordic Bioscience, Herlev, Denmark. 2. Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland. 3. Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia. 4. Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia. 5. Department of Otolaryngology-Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia. 6. Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, Georgia. 7. Biological and Knowledge Analytics, AstraZeneca, Gaithersburg, Maryland.
Abstract
Background: Lupus nephritis (LN) occurs in <40% of patients with SLE. Reliable biomarkers of kidney damage are needed to identify patients with SLE at risk of developing LN to improve screening, treat the disease earlier, and halt progression to kidney failure. Novel biomarkers of extracellular matrix remodeling were evaluated as markers of kidney fibrosis and disease activity in patients with LN. Methods: Biomarkers of the interstitial collagen type III (PRO-C3) and type VI (PRO-C6) formation and of collagen type III (C3M) degradation were evaluated in the serum and urine of 40 patients with LN, 20 patients with SLE but without LN, 20 healthy controls, and ten biopsy controls (histologic kidney inflammation/damage without SLE). Their association with histologic markers of interstitial fibrosis and tubular atrophy, with inflammatory cell infiltration and with disease activity and chronicity in the patients with LN was assessed. Results: Despite PRO-C3 (serum) and PRO-C6 (serum and urine) being significantly elevated in patients with LN compared with healthy controls, the markers did not differentiate patients with LN from those with SLE. C3M (urine) levels were not different in LN compared with the other groups. C3M (urine) strongly correlated and PRO-C6 (serum and urine) inversely correlated with kidney function (eGFR). The biomarkers of interstitial collagen turnover PRO-C6 (serum) and C3M (urine) correlated with histologic markers of interstitial fibrosis, tubular atrophy, and monocyte infiltration. Conclusions: Noninvasive collagen turnover biomarkers are promising tools to identify patients with SLE with kidney histologic modifications.
Background: Lupus nephritis (LN) occurs in <40% of patients with SLE. Reliable biomarkers of kidney damage are needed to identify patients with SLE at risk of developing LN to improve screening, treat the disease earlier, and halt progression to kidney failure. Novel biomarkers of extracellular matrix remodeling were evaluated as markers of kidney fibrosis and disease activity in patients with LN. Methods: Biomarkers of the interstitial collagen type III (PRO-C3) and type VI (PRO-C6) formation and of collagen type III (C3M) degradation were evaluated in the serum and urine of 40 patients with LN, 20 patients with SLE but without LN, 20 healthy controls, and ten biopsy controls (histologic kidney inflammation/damage without SLE). Their association with histologic markers of interstitial fibrosis and tubular atrophy, with inflammatory cell infiltration and with disease activity and chronicity in the patients with LN was assessed. Results: Despite PRO-C3 (serum) and PRO-C6 (serum and urine) being significantly elevated in patients with LN compared with healthy controls, the markers did not differentiate patients with LN from those with SLE. C3M (urine) levels were not different in LN compared with the other groups. C3M (urine) strongly correlated and PRO-C6 (serum and urine) inversely correlated with kidney function (eGFR). The biomarkers of interstitial collagen turnover PRO-C6 (serum) and C3M (urine) correlated with histologic markers of interstitial fibrosis, tubular atrophy, and monocyte infiltration. Conclusions: Noninvasive collagen turnover biomarkers are promising tools to identify patients with SLE with kidney histologic modifications.
Authors: Laura Plantinga; S Sam Lim; Rachel Patzer; William McClellan; Michael Kramer; Mitchel Klein; Stephen Pastan; Caroline Gordon; Charles Helmick; Cristina Drenkard Journal: Arthritis Care Res (Hoboken) Date: 2016-03 Impact factor: 4.794
Authors: Changhu Lee; Min Kim; Jun Ho Lee; Jiyoung Oh; Hyun-Hee Shin; Sang Min Lee; Philipp E Scherer; Hyug Moo Kwon; Jang Hyun Choi; Jiyoung Park Journal: J Pathol Date: 2018-11-27 Impact factor: 7.996
Authors: Daniel Guldager Kring Rasmussen; Anthony Fenton; Mark Jesky; Charles Ferro; Peter Boor; Martin Tepel; Morten Asser Karsdal; Federica Genovese; Paul Cockwell Journal: Sci Rep Date: 2017-12-11 Impact factor: 4.379
Authors: John G Hanly; Aidan G O'Keeffe; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Michelle Petri; Ian N Bruce; Mary Anne Dooley; Rosalind Ramsey-Goldman; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Kristjan Steinsson; Ola Nived; Gunnar K Sturfelt; Susan Manzi; Munther A Khamashta; Ronald F van Vollenhoven; Asad A Zoma; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Thomas Stoll; Murat Inanc; Kenneth C Kalunian; Diane L Kamen; Peter Maddison; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Kara Thompson; Vernon Farewell Journal: Rheumatology (Oxford) Date: 2015-09-05 Impact factor: 7.580